GridAI Technologies (GRDX) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GridAI Technologies (GRDX) has outperformed NextCure (NXTC) over the past year, gaining 20.6% versus a loss of 38.6%. Over five years, NXTC leads with a -91.1% price change compared with -100.0% for GRDX. GridAI Technologies is the larger company by market cap ($32.4 million vs $29.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRDX | NXTC |
|---|---|---|
| Share price | $3.16 | $6.45 |
| Market cap | $32.44M | $29.53M |
| 1-day change | -8.41% | -4.87% |
| YTD return | -32.19% | -54.55% |
| 1-year return | +20.61% | -38.63% |
| 5-year return | -99.99% | -91.07% |
| EPS (TTM) | $-5.65 | $-6.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $36.25K | — |
| Net income (latest FY) | $-6.39M | $-55.84M |
| Gross margin | -1813.56% | — |
| Operating margin | -19539.98% | — |
| Net margin | -17634.42% | — |
| 52-week high | $6.93 | $15.74 |
| 52-week low | $1.87 | $1.55 |
| Distance from 52-week high | -54.39% | -59.02% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +210.08% |
| Average volume | 120.78K | 79.46K |
| Shares outstanding | 10.27M | 4.58M |
| Employees | — | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed NXTC by 59.2 percentage points over the past year.
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Health Care · Biotechnology: Pharmaceutical Preparations
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
GRDX vs NXTC FAQ
Which is bigger, GridAI Technologies or NextCure?
GridAI Technologies (GRDX) is larger, with a market capitalization of $32.44M compared with $29.53M for NextCure (NXTC).
Which stock has performed better over the past year, GRDX or NXTC?
GRDX returned +20.61% over the past 12 months, compared with -38.63% for NXTC (price return, excluding dividends). Past performance does not predict future results.
Are GridAI Technologies and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.